Sowell Financial Services LLC Has $1.09 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sowell Financial Services LLC raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 23.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 49,600 shares of the company’s stock after buying an additional 9,291 shares during the quarter. Sowell Financial Services LLC’s holdings in Teva Pharmaceutical Industries were worth $1,093,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Smithfield Trust Co boosted its position in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after acquiring an additional 980 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at $50,000. Venturi Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth $60,000. Ameliora Wealth Management Ltd. bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $66,000. Finally, Farther Finance Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 273.5% during the third quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock valued at $82,000 after buying an additional 3,323 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $14.69 on Tuesday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The business’s fifty day moving average price is $18.70 and its two-hundred day moving average price is $18.35. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The stock has a market capitalization of $16.65 billion, a price-to-earnings ratio of -10.13, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TEVA shares. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Friday. Bank of America cut their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Finally, Barclays lowered their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.43.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.